Inclusion Criteria:

• A subject must be at least 12 years of age, of either sex, and of any race, with a diagnosis of asthma or COPD of at least 12 months.
• An asthma subject's FEV1 must be >=70% and a COPD subject's FEV1 must be >=50% and have a ratio of FEV1/FVC <=0.70 (pre-bronchodilator).
• An asthmatic subject must have been using a low daily dose of ICS [either alone or in combination with a LABA] for at least 12 weeks and on a stable asthma regimen (daily dose unchanged) for at least 2 weeks prior to Screening.
• A subject must be able to demonstrate correct use of an MDI without a counter at the Screening Visit.
• A subject must demonstrate at least 90% compliance with use of the Counterstrip over the 2-week Screening Period.
• A subject must demonstrate at least 90% compliance with use of study medication over the 2-week Screening Period.
• At the Baseline Visit, an asthma subject's FEV1 or PEF must be >= 80% predicted when all restricted medications have been withheld for the appropriate intervals.
• Clinical laboratory tests, including a chest x-ray (if applicable) must be within normal limits or clinically acceptable to the investigator/sponsor.
• For all female subjects of childbearing potential, serum pregnancy test must be negative.
• An ECG must be clinically acceptable to the investigator/sponsor.
• A subject who experiences an exacerbation that results in ER treatment, hospitalization due to asthma or COPD, or treatment with additional, excluded medication (other than SABA).
• A subject who has been treated in the ER (for a severe exacerbation requiring systemic glucocorticosteroid treatment), or admitted to the hospital for management of airway obstruction within the 3 months prior to the Pre-Screening Visit.
• A subject who has ever required ventilator support for respiratory failure secondary to asthma or COPD.

A subject who has experienced an upper or lower respiratory tract infection (viral or bacterial), including sinus or middle ear infections, within the previous 2 weeks prior to Screening and Baseline Visits.

Exclusion Criteria:

• Subjects who in the judgment of the investigator and/or sponsor have a significant recent or current, repetitive strain injury (RSI) that may impact their ability to effectively participate in the full duration of the study.
• Subjects with a serious uncontrolled medical disorder, which in the judgment of the investigator, could interfere with the study, or require treatment which might interfere with the study.
• An asthmatic subject who demonstrates an increase or decrease in absolute FEV1 of >20% from the Screening Visit to the Baseline Visit.
• An asthmatic subject who experiences a decrease in AM or PM PEF below the Stability Limit on any 2 consecutive days prior to the Baseline Visit.
• An asthmatic subject who requires the use of > 8 inhalations per day of SABA MDI or > 2 nebulized treatments per day of 2.5 mg albuterol, on any 2 consecutive days from the Screening Visit to the Baseline Visit.
• A subject who experiences an exacerbation defined as a clinical deterioration of asthma or COPD, judged by investigator, that results in emergency treatment, hospitalization due to asthma or COPD, or treatment with additional, excluded medication (other than SABA) at any time from the Screening Visit up to and including the Baseline Visit.
• A subject treated in the emergency room (for a severe exacerbation requiring systemic ICS), or admitted to the hospital for management of airway obstruction within the 3 months prior to the Pre-Screening Visit.
• A subject who has ever required ventilator support for respiratory failure secondary to asthma or COPD.
• A subject who has experienced an upper or lower RTI , including sinus or middle ear infections, within the previous 2 weeks prior to Screening and Baseline Visits.